Contribute Try STAT+ Today

Top of the morning, and a fine one it is. Warm and sunny skies are enveloping the Pharmalot campus, where the short person is sleeping in thanks to a week-long break from the usual schoolhouse routine and we are busy brewing cups of stimulation. Feel free to join us. The neurons need a little help now and then, wouldn’t you agree? Meanwhile, we have assembled a few items of interest to help you along. Hope you have a productive day and please keep in touch. We appreciate the suggestions and tips.

A Senate bill to control prescription drug costs seemed to have everything it needed: bipartisan backing, President Trump’s endorsement, and broad public support. But its status on legislative life support reveals the perils of tackling one of the nation’s most hot-button topics months before a presidential election, The Washington Post notes. Even though Trump has said he supports the measure, he has stopped far short of trying to ensure its passage. Meanwhile, the top Senate Republican and Democrat have yet to embrace the legislation, though for opposite reasons.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.